PARP inhibitor olaparib great benefit for a defined group of patients with BRCA positive ovarian cancer
2019
Abstract
Olaparib significantly contributes to prolonging the time to progression and possibly survival in patients with BRCA mutation positive advanced ovarian cancer. The effect is also observed in chemotherapy pretreated patients with metastatic BRCA positive and HER2 negative breast cancer.